PYC Therapeutics Ltd (ASX:PYC) – a clinical biotech company which is progressing the first drug candidate to address childhood blinding eye disease Retinitis Pigmentosa type 11 – will be presenting data from its Phase 1/2 trial at a scientific conference in Singapore by Associate Professor Fred Chen of the Lion’s Eye Institute.
Associate Professor Chen, who works as a consultant ophthalmologist at the Institute as well as Royal Perth Hospital and Perth Children’s Hospital, will be speaking at the Asia Pacific Vitreo-Retina Society (APVRS) on November 23.
The focus of his presentation will be PYC’s ongoing phase 1/2 studies of drug candidate VP-001 in patients with RP11, with a particular focus on improved vision observed in the eye treated with VP-001 when compared to the untreated eye and baseline assessments.
This comes at an important stage for PYC’s development of the candidate, as it prepares to negotiate with the US Food and Drug Administration (FDA) in relation to a registrational
trial for VP-001, anticipated to begin in mid-2025.
Leading up to this, the company will dedicate much of 1H of 2025 to engagement with the FDA around the design of this trial.
PYC shares moved up on this news, and at 13:08 AEDT, they were trading at $1.83 – a rise of 0.55% since the market opened.
Join the discussion: See what HotCopper users are saying about PYC and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
